Home > Products > Primary Cells > Human Primary Cells > Immune System Primary Cells >
Human Diffuse Large B-Cell Lymphoma Bone Marrow Mononuclear Cells (Newly Diagnosed/Untreated) | ||||
|---|---|---|---|---|
| Product Name | Human Diffuse Large B-Cell Lymphoma Bone Marrow Mononuclear Cells (Newly Diagnosed/Untreated) | |||
| Price | Get Quote | |||
| Cat.No | ABC-TC3404 | Species | Human | |
| Size/Quantity | 1 vial | Biosafety Level | 1 | |
| Shipping Info | Dry Ice | Storage | Liquid Nitrogen | |
| Description | Diffuse Large B-Cell Lymphoma-Bone Marrow-Mononuclear Cells are density separated by Ficoll-Paque. Diffuse Large B-Cell LymphomaMononuclear Cells are available in the untreated and relapsed/refractory stages. | |||
| Disease | Diffuse Large B-Cell Lymphoma | |||
| Source Organ | Bone Marrow | |||
| Quality Control | All cells test negative for mycoplasma, bacteria, yeast, and fungi. | |||
| Citation Guide | When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID). | |||
| Application | For research use only | |||
| Growth Conditions | 37 ℃, 5% CO2 | |||
| Cell Type | Mononuclear Cell | |||
| Growth Mode | Adherent | |||
| Product Type | Immune Cells | |||
| Product Image |  | |||
- ONLINE INQUIRY
- PRODUCT REVIEWS
We know how valuable your research is to you, but are you wondering what you can expect to pay for quick accurate results every time?
Fill out a request in the form below and we’ll get back to you within 24 hours with a quote.
Fill out a request in the form below and we’ll get back to you within 24 hours with a quote.
Privacy Policy: AcceGen will never sell, rent, or share your personal information with any third parties without your express permission.
Reviews of Human Diffuse Large B-Cell Lymphoma Bone Marrow Mononuclear Cells (Newly Diagnosed/Untreated)
AcceGen is always trying to do right by our customers and working hard to build a higher quality product.
